FAQ - Why Can’t Other Top Cancer Centers Offer Envita’s Precision Oncology Options?

In standard cancer treatment today, patients are often not given precision medicine. Dr. Dino Prato and Dr. John Oertle explain how they offer innovative oncology care by overcoming barriers that limit its practice in standard cancer centers.
Conventional oncologists are generally not trained in precision oncology, and the adoption of newer technologies in oncology care is slow. Cancer research studies, such as the Duke University Molecular Tumor Board, have shown that many patients do not receive evidence-based biomarker testing that could connect them to appropriate therapies or clinical trials.
To address the lack of access to precision oncology, Envita Medical Centers and Center of Excellence follow precision oncology for every patient. However, major cancer care facilities in the United States typically allow access to precision care options only after patients fail to respond to their initial treatment, according to the National Cancer Institute (NCI) guidelines.
The National Comprehensive Cancer Network (NCCN) guidelines, based on cancer stage and type, may not work for all patients. Similar cancer patients may have different outcomes despite undergoing the same therapies, emphasizing the need for precision oncology treatment options.
At Envita, every patient has access to precision oncology treatment options from the beginning. Health care providers undergo extensive training and observation to become proficient in Envita's unique genomic molecular targeting, immunotherapy oncology, and precision informatics algorithms. These algorithms have been developed over two decades of clinical practice, focusing on late-stage cancer patients who did not respond to standard treatments elsewhere.
Envita's approach relies on detailed genomic testing to guide appropriate therapeutics. They have been following this approach for over two decades, putting them ahead in precision oncology based on clinical experiences and public literature.
Envita believes that cancer is not solely a disease of tissue or organs, but a disease of messaging, micro-environment, immunity, biomarkers, and evasion of death by cancer cells. Their treatment approach takes into account these factors and approaches cancer with detailed information, providing advantages for patients.
The NIH-funded I-PREDICT clinical trial revealed that analyzing a tumor's genetic and molecular profile provided information to recommend individualized combination therapies. Envita's approach aligns with these findings and helps optimize patient outcomes in late-stage patients who were unresponsive to standard treatment facilities.
However, Envita's unique approach is not yet available in standard cancer treatment facilities due to a lack of required infrastructure. Their precision integrative oncology combines conventional medicine with research-based integrative medicine and natural therapies, benefiting both late-stage and early-stage cancers by identifying and proactively treating early signs of metastatic spread.
Envita takes pride in their forward-thinking care approach and considers it an honor to have the ability to provide such care.
To get a hold of a patient care coordinator today call us at: 1-866-830-4576
To receive information about a condition you may be dealing with visit www.envita.com...
Visit out website to learn more: www.envita.com/